Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
26 août 2024 17h23 HE
|
Lifecore Biomedical, Inc.
-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% ---- High Value Pipeline Continues to Advance Toward Commercialization ---- State-of-the-Art Technology...
Lifecore Biomedical Announces Cooperation Agreement with 22NW
01 juil. 2024 08h00 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 mai 2024 16h16 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., May 22, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization, today...
Lifecore Biomedical Completes Incremental Liquidity Initiatives
16 mai 2024 16h45 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
19 avr. 2024 16h30 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the...
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
01 avr. 2024 08h00 HE
|
Lifecore Biomedical, Inc.
Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Provides Fiscal 2024 Full Year Guidance Commercial Momentum Continues within Development Portfolio ...
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
26 mars 2024 16h30 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
20 mars 2024 07h30 HE
|
Lifecore Biomedical, Inc.
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board...
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
20 mars 2024 07h00 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
16 févr. 2024 16h05 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that on February 13, 2024 it received a Staff Delisting Determination (the...